<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04936607</url>
  </required_header>
  <id_info>
    <org_study_id>ICM 2022-2949</org_study_id>
    <nct_id>NCT04936607</nct_id>
  </id_info>
  <brief_title>ImproviNg rEnal Outcomes Following Coronary angiograPhy and/or percuTaneoUs coroNary intErventions</brief_title>
  <acronym>NEPTUNE</acronym>
  <official_title>ImproviNg rEnal Outcomes Following Coronary angiograPhy and/or percuTaneoUs coroNary intErventions: a Pragmatic, Adaptive, Patient-oriented Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guillaume Marquis-Gravel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Montreal Heart Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The NEPTUNE triple-blind, active-placebo, adaptive, pragmatic, randomized trial aims to&#xD;
      evaluate the effectiveness of a new intra-venous hydration strategy guided by left&#xD;
      ventricular end-diastolic pressure (LVEDP), amount of contrast used, and baseline renal&#xD;
      function, to prevent contrast-induced acute kidney injury (CI-AKI) and patient-oriented&#xD;
      clinical endpoints in all-comer patients undergoing coronary angiogram and/or percutaneous&#xD;
      coronary intervention (PCI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All-comer patients undergoing a coronary angiogram and/or a PCI and meeting the eligibility&#xD;
      criteria will be randomized to be treated with either a hydration strategy personalized to&#xD;
      LVEDP, amount of contrast used, and baseline renal function, or to standard, non-tailored&#xD;
      hydration (1:1 allocation ratio stratified by GFR ≥60 vs. &lt;60 mL/min/1.73 m2). The operators&#xD;
      (interventional cardiologists and fellows) and the participants will be blinded to the&#xD;
      treatment allocation during the procedure. Serum creatinine will be measured at 48 hours, 7&#xD;
      days, and 6 months after the procedure, and the incidence of contrast-induced acute kidney&#xD;
      injury (CI-AKI) (primary endpoint) and of major adverse renal and cardiovascular events will&#xD;
      be evaluated by a blinded and independent expert adjudication committee.&#xD;
&#xD;
      All participants will be treated with a commercially available 0.9% NaCl solution (normal&#xD;
      saline, NS) infusion at a rate of 3 mL/kg/h for one hour prior to the procedure. In both&#xD;
      study groups, LVEDP will be measured at the beginning of the procedure by introducing a&#xD;
      catheter in the left ventricle, as performed routinely in clinical practice. In the&#xD;
      experimental group, NS infusion rate will be adjusted based on LVEDP for the whole duration&#xD;
      of the procedure (&lt;13 mmHg: 5 ml/kg/h; 13-18 mmHg: 3 ml/kg/h; &gt;18 mmHg: 1.5 ml/kg/h), or for&#xD;
      one hour, whichever is the longest. After the procedure, and for a duration of 4 hours, the&#xD;
      hydration rate will be adjusted based on the (contrast volume:estimated glomerular filtration&#xD;
      rate (eGFR)) ratio, according to the following scheme: 1.5 ml/kg/h if contrast volume/eGFR&#xD;
      ratio &lt;2.0; 3 ml/kg/h for contrast volume/eGFR ratio 2.0-2.9; 5 ml/kg/h for contrast&#xD;
      volume/eGFR ratio ≥3.0. In the control group, infusion rate will be of 1.5 ml/kg/h during the&#xD;
      procedure, and for the 4 following hours.&#xD;
&#xD;
      This study will follow an adaptive design in which the primary endpoint will be shifted to a&#xD;
      more patient-oriented endpoint at the time of a single interim analysis according to&#xD;
      pre-specified criteria established in the protocol. The adaptive design will allow to stop&#xD;
      the trial if the experimental strategy is futile to reduce the rates of CI-AKI, and to&#xD;
      continue on an operationally seamless manner if the experimental strategy is beneficial to&#xD;
      reduce CI-AKI, transitioning to major adverse renal and cardiovascular endpoints (MARCE) as&#xD;
      the primary endpoint.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast-induced acute kidney injury</measure>
    <time_frame>7 days</time_frame>
    <description>Increase in creatinine of 1.5 times baseline within 7 days or increase in creatinine by 26.5 umol/L (i.e. 0.3 mg/dL) within 48 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse renal and cardiovascular events (MARCE)</measure>
    <time_frame>6 months</time_frame>
    <description>Composite of death, myocardial infarction, stroke, or renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MARCE composite with the addition of persistent increase of at least 50% from baseline serum creatinine</measure>
    <time_frame>6 months</time_frame>
    <description>MARCE composite with the addition of persistent increase of at least 50% from baseline serum creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>6 months</time_frame>
    <description>All-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>6 months</time_frame>
    <description>Myocardial infarction (types 1-5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>6 months</time_frame>
    <description>Ischemic, hemorrhagic, or undetermined stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy</measure>
    <time_frame>6 months</time_frame>
    <description>Any type of renal replacement therapy (dialysis, hemofiltration, hemodiafiltration, or other)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic kidney disease</measure>
    <time_frame>6 months</time_frame>
    <description>50% increase from baseline serum creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening of kidney disease</measure>
    <time_frame>6 months</time_frame>
    <description>Transition to a higher KDIGO CKD stage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length-of-stay</measure>
    <time_frame>6 months</time_frame>
    <description>Hospital length-of-stay after the procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1158</enrollment>
  <condition>Contrast-Induced Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Personnalized hydration strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the experimental group, NS infusion rate will be adjusted based on LVEDP for the whole duration of the procedure (&lt;13 mmHg: 5 ml/kg/h; 13-18 mmHg: 3 ml/kg/h; &gt;18 mmHg: 1.5 ml/kg/h), or for one hour, whichever is the longest. After the procedure, and for a duration of 4 hours, the hydration rate will be adjusted based on the (contrast volume:estimated glomerular filtration rate (eGFR)) ratio, according to the following scheme: 1.5 ml/kg/h if contrast volume/eGFR ratio &lt;2.0; 3 ml/kg/h for contrast volume/eGFR ratio 2.0-2.9; 5 ml/kg/h for contrast volume/eGFR ratio ≥3.0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the control group, infusion rate will be of 1.5 ml/kg/h during the procedure, and for the 4 following hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Personalized hydration strategy</intervention_name>
    <description>In the experimental group, NS infusion rate will be adjusted based on LVEDP for the whole duration of the procedure (&lt;13 mmHg: 5 ml/kg/h; 13-18 mmHg: 3 ml/kg/h; &gt;18 mmHg: 1.5 ml/kg/h), or for one hour, whichever is the longest. After the procedure, and for a duration of 4 hours, the hydration rate will be adjusted based on the (contrast volume:estimated glomerular filtration rate (eGFR)) ratio, according to the following scheme: 1.5 ml/kg/h if contrast volume/eGFR ratio &lt;2.0; 3 ml/kg/h for contrast volume/eGFR ratio 2.0-2.9; 5 ml/kg/h for contrast volume/eGFR ratio ≥3.0.</description>
    <arm_group_label>Personnalized hydration strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>In the control group, infusion rate will be of 1.5 ml/kg/h during the procedure, and for the 4 following hours.</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years;&#xD;
&#xD;
          -  Planned coronary angiogram and/or PCI;&#xD;
&#xD;
          -  Willingness to participate and to attend study visits;&#xD;
&#xD;
          -  Expected life expectancy ≥6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiogenic or non-cardiogenic shock at the time of the procedure;&#xD;
&#xD;
          -  Emergent procedures (e.g. STEMI);&#xD;
&#xD;
          -  Iodine-based contrast media received within 2 days;&#xD;
&#xD;
          -  Presence of Intra-Aortic Balloon Pump (IABP);&#xD;
&#xD;
          -  Cardiac arrest within 24 hours;&#xD;
&#xD;
          -  Pre-procedural AKI defined using the modified KDIGO criteria within 7 days;&#xD;
&#xD;
          -  Renal replacement therapy;&#xD;
&#xD;
          -  Severe aortic or mitral disease;&#xD;
&#xD;
          -  LVEF &lt;30%.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume Marquis-Gravel, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume Marquis-Gravel, MD, MSc</last_name>
    <phone>(514) 376-3330</phone>
    <email>guillaume.marquis.gravel@umontreal.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Marquis-Gravel, MD, MSc</last_name>
      <phone>9195193271</phone>
      <email>guillaume.marquis.gravel@umontreal.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Montreal Heart Institute</investigator_affiliation>
    <investigator_full_name>Guillaume Marquis-Gravel</investigator_full_name>
    <investigator_title>Assistant professor, Université de Montreal</investigator_title>
  </responsible_party>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Pragmatic trial</keyword>
  <keyword>Adaptive trial</keyword>
  <keyword>Patient-oriented trial</keyword>
  <keyword>Contrast-induced Nephropathy</keyword>
  <keyword>Acute Kidney Injury</keyword>
  <keyword>Coronary angiography</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD sharing plan.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

